BioNexus Gene Lab
BGLC
2 hedge funds and large institutions have $497 invested in BioNexus Gene Lab in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
2.01% less ownership
Funds ownership: 2.02% → 0.01% (-2%)
100% less capital invested
Capital invested by funds: $189K → $497 (-$188K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$629 |
| 2 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$189K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $495 | +$629 | +231 | New |
|
|
2
Wells Fargo
San Francisco,
California
| $2 | +$3 | +1 | New |
|
|
DS
3
DRW Securities
Chicago,
Illinois
| – | -$189K | -47,830 | Closed |
|
BGLC Hedge Fund Activity: Q1 2026 in Review
2 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q1 2026, worth a combined $497 — down 100% from $189K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BGLC positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $629. The largest seller was DRW Securities, exiting entirely with an estimated $189K sold.
- 2 institutional investors held BioNexus Gene Lab (BGLC) as of Q1 2026, up from 1 in Q4 2025.
- Funds reported $497 of BioNexus Gene Lab stock for Q1 2026, down 100% quarter-over-quarter.
- 2 funds opened new BioNexus Gene Lab positions in Q1 2026 and 1 closed out, a net change of +1 holder.
- The largest BioNexus Gene Lab buyer in Q1 2026 was UBS Group, an estimated $629 added.
- The largest BioNexus Gene Lab seller in Q1 2026 was DRW Securities, an estimated $189K sold.
Based on aggregated 13F filings for Q1 2026.